Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CX-188

Monoclonal antibody · Immune activation, directed at programmed cell death protein 1 (PDCD1) · developed by CytomX Therapeutics

Phase 1 Most advanced trial (none active)
CTMX Developer
1 Registered trials

What is CX-188?

CX-188 is a probody, an anti-PD-1 monoclonal antibody whose antigen-binding site is masked by a peptide linked through a protease-cleavable linker. Tumor-associated proteases in the tumor microenvironment cleave the mask, letting the antibody bind PD-1 and disrupt its inhibitory signaling to restore T-cell activity. It is studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
programmed cell death protein 1 (PDCD1)
Mechanism
Immune activation, directed at programmed cell death protein 1 (PDCD1)
Pathways
PD-1 signaling, T-cell activation
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03706274 Phase 1 Solid Tumor, Adult Withdrawn CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor, Adult

Other drugs acting on PDCD1

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind CX-188

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.